A phase II clinical trial has been recently completed to evaluate the immune responses of melanoma-specific peptide vaccines, gp100 and MAGE-3 in the presence or absence of Leuprolide, a LHRH-agonist (NCT00254397) in patients with stage II-IV melanoma whose lesions are surgically removed. The gene discussed is MAGEA3; the disease is melanoma.